Goldman Sachs Boosts HANSOH PHARMA Price Target on Strong First-Half Results

Stock News08-27 17:32

Goldman Sachs has released a research report indicating that HANSOH PHARMA (03692) delivered first-half results that surpassed expectations, driven by innovative drug sales, operational leverage, and investment gains. As a result, the investment bank has raised its price target from HK$50.1 to HK$52.7 while also increasing its 2026 earnings forecast by 15%, maintaining a "Buy" rating on the stock.

Management has reiterated its guidance for double-digit growth in both product sales and business development (BD) revenue for the 2026 fiscal year, supported by a robust product pipeline and expectations of a new product cycle beginning in 2027. The firm believes that the second wave of innovative products and the ADC (antibody-drug conjugate) product series will serve as key growth drivers, enabling the company to diversify its portfolio beyond a single product and underpin sustainable long-term growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165986970?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 17:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165986970","market":"other","top_or_hot":-1,"title":"Goldman Sachs Boosts HANSOH PHARMA Price Target on Strong First-Half Results","media":"Stock News","content":"<p>Goldman Sachs has released a research report indicating that <b>HANSOH PHARMA</b> (03692) delivered first-half results that surpassed expectations, driven by innovative drug sales, operational leverage, and investment gains. As a result, the investment bank has raised its price target from HK$50.1 to HK$52.7 while also increasing its 2026 earnings forecast by 15%, maintaining a \"Buy\" rating on the stock.<br><br>Management has reiterated its guidance for double-digit growth in both product sales and business development (BD) revenue for the 2026 fiscal year, supported by a robust product pipeline and expectations of a new product cycle beginning in 2027. The firm believes that the second wave of innovative products and the ADC (antibody-drug conjugate) product series will serve as key growth drivers, enabling the company to diversify its portfolio beyond a single product and underpin sustainable long-term growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs Boosts HANSOH PHARMA Price Target on Strong First-Half Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs Boosts HANSOH PHARMA Price Target on Strong First-Half Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-27 17:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Goldman Sachs has released a research report indicating that <b>HANSOH PHARMA</b> (03692) delivered first-half results that surpassed expectations, driven by innovative drug sales, operational leverage, and investment gains. As a result, the investment bank has raised its price target from HK$50.1 to HK$52.7 while also increasing its 2026 earnings forecast by 15%, maintaining a \"Buy\" rating on the stock.<br><br>Management has reiterated its guidance for double-digit growth in both product sales and business development (BD) revenue for the 2026 fiscal year, supported by a robust product pipeline and expectations of a new product cycle beginning in 2027. The firm believes that the second wave of innovative products and the ADC (antibody-drug conjugate) product series will serve as key growth drivers, enabling the company to diversify its portfolio beyond a single product and underpin sustainable long-term growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1165986970","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165986970","pubTimestamp":1787823160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Goldman Sachs has released a research report indicating that HANSOH PHARMA (03692) delivered first-half results that surpassed expectations, driven by innovative drug sales, operational leverage, and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","EWH":"香港ETF-iShares MSCI","03692":"翰森制药","BK1583":"高瓴概念","BK1589":"北水核心资产"},"translate_title":"高盛因强劲上半年业绩上调豪森制药目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1,"EWH":1},"content_text":"Goldman Sachs has released a research report indicating that HANSOH PHARMA (03692) delivered first-half results that surpassed expectations, driven by innovative drug sales, operational leverage, and investment gains. As a result, the investment bank has raised its price target from HK$50.1 to HK$52.7 while also increasing its 2026 earnings forecast by 15%, maintaining a \"Buy\" rating on the stock.Management has reiterated its guidance for double-digit growth in both product sales and business development (BD) revenue for the 2026 fiscal year, supported by a robust product pipeline and expectations of a new product cycle beginning in 2027. The firm believes that the second wave of innovative products and the ADC (antibody-drug conjugate) product series will serve as key growth drivers, enabling the company to diversify its portfolio beyond a single product and underpin sustainable long-term growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165986970","isCrawlerRequest":true}